Langerhans-Cell Histiocytosis A spectrum of diseases formerly known as histiocytosis X and
now called Langerhans-cell histiocytosis is characterized by ERK pathway activation …

Histiocytoses constitute a heterogeneous group of rare disorders, characterised by
infiltration of almost any organ by myeloid cells with diverse macrophage or dendritic cell …

PURPOSE Off-label use of vemurafenib (VMF) to treat BRAFV600E mutation–positive,
refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. PATIENTS AND …

Langerhans cell histiocytosis (LCH) is a rare systemic disorder characterized by the
accumulation of CD 1a+/Langerin+ LCH cells and wide‐ranging organ involvement …

Langerhans cell histiocytosis (LCH) is a rare neoplastic disorder caused by somatic genetic
alterations in hematopoietic precursor cells differentiating into CD1a+/CD207+ histiocytes …

Langerhans cell histiocytosis (LCH) is a disorder with a variety of clinical signs. The most
severe forms affect risk organs (RO). The established role of the BRAF V600E mutation in …

Neurodegenerative (ND) complications in Langerhans cell histiocytosis (LCH) are a late‐
onset but dramatic sequelae for which incidence and risk factors are not well defined. Based …

In recent years, detection of cell‐free tumour DNA (ct DNA) or liquid biopsy has emerged as
an attractive noninvasive methodology to detect cancer‐specific genetic aberrations in …

Langerhans cell histiocytosis (LCH) is a neoplasm marked by the accumulation of CD1A+
CD207+ cells. It is most commonly driven by a somatic, activating mutation in the BRAF …

Pulmonary Langerhans cell (LC) histiocytosis (PLCH) has unknown cause and is a rare
neoplastic disorder characterized by the infiltration of lungs and various organs by bone …